Department of General Practice, University College Cork, Cork, Ireland.
School of Economics, University College Cork, Cork, Ireland.
Eur J Clin Pharmacol. 2019 Dec;75(12):1713-1722. doi: 10.1007/s00228-019-02750-w. Epub 2019 Aug 28.
Medication errors during transitional care are an important patient safety issue. Medication reconciliation is an established intervention to reduce such errors. Current evidence has not demonstrated an associated reduction in healthcare costs, however, with complexity and resource intensity being identified as issues. The aims of this study were to examine an existing process of medication reconciliation in terms of time taken, to identify factors associated with additional time, and to determine if additional time is associated with detecting errors of clinical significance.
A cross-sectional study was conducted. Issues arising during medication reconciliation incurring a time burden additional to the usual process were logged and quantified by pharmacists. Regression analyses investigated associations between patient characteristics and clinically significant errors and additional time. Cost for additional time in terms of hospital pharmacist salary was calculated.
Eighty-nine patients were included. Having a personal record of medication at admission (OR 3.30, 95% CI: (1.05 to 10.42), p = 0.004) was a significant predictor of additional time. No significant associations were found between the occurrence of clinically significant error and additional time (p > 0.05). The most common reason for additional time was clarifying issues pertaining to primary care medication information. Projected annual 5-year costs for the mean additional time of 3.75 min were €1.8-1.9 million.
Spending additional time on medication reconciliation is associated with economic burden and may not yield benefit in terms of capturing clinically significant errors. There is a need to improve communication of medication information between primary and secondary care.
过渡护理期间的用药错误是一个重要的患者安全问题。用药核对是减少此类错误的既定干预措施。然而,目前的证据并未表明医疗成本降低,复杂性和资源密集度被认为是存在的问题。本研究的目的是检查用药核对的现有流程,了解所需时间,确定与额外时间相关的因素,并确定额外时间是否与检测到具有临床意义的错误相关。
本研究采用横断面研究。药剂师记录并量化了用药核对过程中产生的额外时间负担的相关问题。回归分析调查了患者特征与临床显著错误和额外时间之间的关联。根据医院药剂师的工资计算了额外时间的成本。
共纳入 89 名患者。入院时个人用药记录(OR 3.30,95%CI:(1.05 至 10.42),p=0.004)是额外时间的显著预测因素。临床显著错误的发生与额外时间之间无显著关联(p>0.05)。额外时间最常见的原因是澄清与初级保健药物信息相关的问题。平均额外时间为 3.75 分钟的 5 年预计年度费用为 180 万至 190 万欧元。
在用药核对上花费额外的时间与经济负担有关,并且可能不会在捕捉具有临床意义的错误方面带来益处。有必要改善初级保健和二级保健之间的药物信息沟通。